Published in Law and Health Weekly, April 15th, 2006
"Exenatide is an incretin mimetic whose effect on glycemic control in patients with type 2 diabetes is currently under investigation. This study assessed the effect of injection time relative to a standardized meal on postprandial pharmacodynamics of exenatide in patients with type 2 diabetes," researchers in England report.
H. Linnebjerg and colleagues at Eli Lilly explained, "Eighteen patients participated in this single-center, open-label, placebo-controlled, randomized, six-way crossover study. Patients received subcutaneous injections of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.